Aclaris Therapeutics, Inc. (ACRS) saw its loss narrow to $12.56 million, or $0.48 a share for the quarter ended Mar. 31, 2017. In the previous year period, the company reported a loss of $13.04 million, or $0.65 a share. The company has not recorded any revenues for the current as well as previous quarter.
Operating loss for the quarter was $12.93 million, compared with an operating loss of $13.14 million in the previous year period.
"The start of 2017 has been a busy one for Aclaris and we are pleased the momentum from last year has continued into the first quarter of this year," commented Dr. Neal Walker, president and chief executive officer of Aclaris. "Our New Drug Application (NDA) for A-101 40% Topical Solution (A-101 40%) for the treatment of seborrheic keratosis (SK) was accepted for review by the U.S. Food and Drug Administration (FDA). We continue to advance our pipeline and broaden our intellectual property estate as we focus our efforts on developing innovative treatments for patients."
Disclaimer: Please note that this is an auto-generated article. IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website. For queries contact: [email protected]
